Company Now Holds Over 100 BTC as Part of Long-Term Growth Strategy
ATLANTA, June 13, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced it has purchased additional Bitcoin (BTC) as part of its treasury strategy first initiated in June 2024.
The move follows the Company’s earlier purchases of 51 and 11 BTC in February 2025. With this latest addition, Bitcoin Depot now holds over 100 BTC in its treasury, further reinforcing its belief in Bitcoin’s long-term potential as both a strategic asset and a store of value.
“As the digital asset landscape continues to evolve during a period of strong industry momentum and innovation, we view Bitcoin as a foundational piece of our long-term growth strategy, and this purchase is a continuation of that conviction,” said Brandon Mintz, CEO and founder of Bitcoin Depot. “As we expand our treasury and our footprint, we remain committed to enabling access to Bitcoin and aligning with its future.”
This announcement comes as Bitcoin continues to experience significant momentum in 2025, marked by policy and regulatory clarity, growing institutional demand, increased adoption, and the recent all-time price high of over $111,000.
Bitcoin Depot’s latest BTC purchase also follows a wave of strong business growth for the Company, including the recent strategic acquisition of regional operator Pelicoin’s assets to further strengthen its market leadership. Today, Bitcoin Depot operates the largest Bitcoin ATM network in North America, with more than 8,500 locations and a growing international footprint.
The financial terms of the transaction were not disclosed. For more information, visit www.bitcoindepot.com.
About Bitcoin Depot Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 47 states and at thousands of name-brand retail locations in 31 states through its BDCheckout product. The Company has the largest market share in North America with over 8,500 kiosk locations as of June 2025. Learn more at www.bitcoindepot.com.
Cautionary Note Regarding Forward-Looking Statements This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations of plans, business strategies, objectives and growth and anticipated financial and operational performance, including our growth strategy and ability to increase deployment of our products and services, the anticipated effects of the Amendment, and the closing of the Preferred Sale. These forward-looking statements are based on management’s current beliefs, based on currently available information, as to the outcome and timing of future events. Forward-looking statements are often identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,” “plan,” “potential,” “priorities,” “project,” “pursue,” “seek,” “should,” “target,” “when,” “will,” “would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these judgments are reasonable, but these statements are not guarantees of any future events or financial results. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond our control.
These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the business combination; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; our ability to manage future growth; our ability to develop new products and services, bring them to market in a timely manner and make enhancements to our platform; the effects of competition on our future business; our ability to issue equity or equity-linked securities; the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries; and those factors described or referenced in filings with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change.
We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement.
Toronto, Ontario–(Newsfile Corp. – June 13, 2025) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) announces that its shareholders approved all resolutions at the Company’s Annual and Special Meeting of Shareholders (the “Meeting”) which was held on Thursday, June 12, 2025. The formal part of the Meeting was followed by an update from Aurania’s President & CEO, Dr. Keith Barron. To access the replay of Dr. Barron’s update on YouTube, click this link: https://youtu.be/m0SIk501QtY
At the Meeting, shareholders approved the financial statements for the year-ended December 31, 2024, and the report of the auditors thereon, the appointment of auditors, election of directors, and the Company’s incentive stock option plan for the upcoming year. Details of these matters are disclosed in the Management Information Circular for the Meeting dated April 30, 2025, and posted under the Company’s profile on www.sedarplus.ca and on the Company’s corporate website http://www.aurania.com/investors/annual-general-meeting/.
Clarification to Press Release Dated June 11, 2025
Further to the Company’s press release dated June 11, 2025, the Company wishes to clarify the terms of the proposed fee that the Company would be required to pay as presented by ARCOM. As currently contemplated, half of this fee is expected to be due by July 31, 2025, and the remaining 50% is expected to be due by January 31, 2026.
About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper in South America. Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis
Led launch of Tonix Medicines, acquisition of migraine assets Zembrace® SymTouch® and Tosymra®, and recruitment of commercial leadership team
Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year
CHATHAM, N.J., June 13, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the appointment of James “Jim” Hunter to its Board of Directors, effective June 12, 2025. Mr. Hunter most recently served as Executive Vice President, Commercial at Tonix, where he was responsible for building the Company’s commercial subsidiary, Tonix Medicines, and successfully executing its entry into the migraine market.
“Jim’s appointment to our Board comes at a pivotal moment as we continue to expand our commercial footprint and intensify our pre-commercial efforts for the potential launch of TNX-102 SL for fibromyalgia later this year,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Having successfully built Tonix Medicines from the ground up, Jim brings a unique operational perspective and deep commercial expertise that will be invaluable as we advance our commercial strategy and long-term growth.”
In his role as Executive Vice President of Commercial Operations at Tonix Pharmaceuticals and President of Tonix Medicines from June 2023 to December 2024, Mr. Hunter was responsible for managing all aspects of Tonix’s commercial efforts, including sales, marketing, market access and other operational and strategic initiatives. In addition to its ongoing commercial activities with respect Tosymra and Zembrace, Tonix Medicines is actively involved in TNX-SL 102 pre-launch activities including launch strategy, market analysis, product positioning, and market access initiatives.
Previously, Mr. Hunter was CEO and Co-founder of Validus Pharmaceuticals from 2007 to 2018, where he was responsible for more than two dozen successful product acquisitions from companies such as Shire, Roche, Novartis and Sanofi. Jim was also Co-Founder of Relialab, a diagnostics company focused on CLIA-waived, point-of-care psychiatric testing. Prior to these ventures, Mr. Hunter was Executive Director of Neuroscience Sales at Novartis Pharmaceuticals, where he launched and supported products in schizophrenia, epilepsy, migraine, Parkinson’s and Alzheimer’s. Mr. Hunter also served as Executive Director of the Northeast Business Unit at Ciba Geigy Pharmaceuticals, where he was responsible for the General Practice and hospital sales force and Regional Managed Care. Mr. Hunter received his B.S. at Seton Hall University and earned his M.B.A at Fairleigh Dickinson University.
“I’m honored to join Tonix’s Board at such an exciting juncture,” said Mr. Hunter. “It’s been a privilege to help build Tonix Medicines and launch the Company’s commercial capabilities. I look forward to continuing to support Tonix’s mission as a member of the Board and contributing to its next phase of growth.”
“I’m grateful to Jim for creating and building our commercial department which has positioned us well to launch TNX-102 SL for the management of fibromyalgia,” said Thomas Englese, EVP of Commercial Operations and leader of Tonix Medicines. “Jim’s continued strategic involvement as we prepare for the launch and continue to build our commercial infrastructure will be incredibly valuable.”
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years. TNX-4200 is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.
Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.
Important Safety Information
Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:
discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
pain or discomfort in your arms, back, neck, jaw or stomach
shortness of breath with or without chest discomfort
breaking out in a cold sweat
nausea or vomiting
feeling lightheaded
Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.
Do not use Zembrace or Tosymra if you have:
history of heart problems
narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
uncontrolled high blood pressure
hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
severe liver problems
taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
an allergy to sumatriptan or any of the components of Zembrace or Tosymra
Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.
Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.
Zembrace and Tosymra may cause serious side effects including:
changes in color or sensation in your fingers and toes
sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
hives (itchy bumps); swelling of your tongue, mouth, or throat
seizures even in people who have never had seizures before
The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).
Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.
This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.
You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Key Points: – Small-cap defense companies operate in specialized sectors with higher agility and acquisition potential compared to mega-cap contractors – Cybersecurity, drone systems, and advanced materials offer the strongest growth opportunities in current geopolitical climate – Market volatility creates entry opportunities before institutional recognition drives valuations higher
While major defense contractors like Lockheed Martin and Northrop Grumman capture headlines during geopolitical tensions, astute small-cap investors should turn their attention to the lesser-known defense players positioned to benefit from increased military spending and technological innovation. Small-cap defense companies often operate in specialized niches that make them indispensable to larger prime contractors and government agencies, and unlike their mega-cap counterparts, these firms can pivot quickly to emerging threats and technologies, making them attractive acquisition targets or compelling long-term growth stories.
The current geopolitical climate, highlighted by recent Middle East tensions and ongoing global conflicts, has created a sustained tailwind for defense spending. President Trump’s pledge of a $1 trillion defense budget, while potentially falling short in fiscal 2026, signals a multi-year commitment to military modernization that extends far beyond traditional weapons systems. This environment particularly benefits small-cap companies specializing in cybersecurity and electronic warfare, where firms focusing on cyber defense, electronic countermeasures, and signal intelligence are experiencing unprecedented demand. These companies often possess proprietary technologies that are difficult to replicate and command premium margins, creating substantial competitive advantages.
The drone revolution presents another compelling opportunity, extending beyond consumer applications into military reconnaissance, logistics, and combat operations. Small-cap manufacturers of specialized UAV components, software, and support systems are capturing market share from traditional aerospace giants, while companies developing next-generation materials for armor, stealth applications, and extreme environment operations often fly under the radar while generating substantial returns for early investors.
When evaluating small-cap defense opportunities, successful investors focus on companies with government contract diversification across multiple agencies and international allies to reduce single-customer risk. The most attractive investments typically feature proprietary technology through patents and specialized expertise that create competitive moats justifying premium valuations. Experienced management teams with deep defense industry connections and security clearances consistently accelerate contract wins, while financial discipline demonstrated through strong balance sheets and consistent cash flow generation proves crucial despite the lumpy nature of contract timing.
Small-cap defense investing requires careful risk assessment, as government budget cycles, security clearance requirements, and regulatory compliance create unique challenges. However, companies that successfully navigate these hurdles often enjoy sustained competitive advantages and multi-year revenue visibility that reward patient investors. The current environment of elevated geopolitical tensions, combined with technological disruption in warfare, creates an ideal backdrop for small-cap defense investments. While large-cap names grab immediate attention during crisis periods, the real long-term value creation often occurs in the innovative small companies that power the next generation of military capabilities. Smart investors should use market volatility as an opportunity to build positions in quality small-cap defense names before institutional recognition drives valuations higher.
Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Noble Virtual Conference. On June 4, the company presented at the Noble Virtual Conference to the investment community. The presentation conducted by Heidy Chow, CFO, and Peter Lin, Sr. Manager, FP&A, highlighted the company’s release roadmap, unique product offerings, and portfolio diversification. A replay of the presentation can be viewed here.
Favorable release roadmap. The company has a busy release roadmap for 2025, which includes a 10th-anniversary expansion pack for ARK: Survival Evolved, a new expansion pack for ARK: Survival Ascended, and the release of Bellwright on Xbox in Q4. Additionally, nine new gaming titles are slated for 2025, including Robots at Midnight, Honeycomb, and Echoes of Elysium, which could have breakout potential. Additionally, the company recently expanded into new entertainment categories to further expand its portfolio.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Updating estimates. While we are maintaining our 2025 rail car delivery estimate of 4,710, we have lowered our second quarter expectations to 850 from 950 and increased our third quarter estimate to 1,790 from 1,690. Our 2025 EBITDA and EPS estimates are unchanged at $45.9 million, and $0.47, respectively. However, our second and third quarter EPS estimates are $0.06 and $0.20, respectively, compared to our prior estimates of $0.07 and $0.19.
Flexible production schedule. With FreightCar’s asset-based lending facility, the company has greater flexibility to manage its production schedule, given that it can borrow against inventory. The company has the ability to produce rail cars associated with firm orders and hold them for delivery to suit customer needs.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Bolsters its southern operations. On June 11, the company announced that it had acquired the assets of Pelicoin, a crypto ATM company with operations in the Gulf South (particularly MS, AL, TX, TN). The additional kiosks, which we believe to be roughly 50, are expected to be fully integrated within several weeks.
Industry consolidation. In our view, the acquisition demonstrates the attractive industry consolidation opportunity for the company. Notably, the Pelicoin acquisition marks the second time in the last 18 months that the company has opportunistically added to its kiosk fleet. In April 2024, the company acquired 2,300 kiosks at a 50% discount from a defunct operator. We believe, with its healthy cash balance of $35 million (as of 3/31/25), the company is well positioned to continue to consolidate the industry as opportunities arise.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Stripe’s acquisition of crypto wallet provider Privy represents far more than a simple technology purchase—it’s a calculated move to position the payments giant at the forefront of the digital currency revolution. This strategic acquisition, coming on the heels of Stripe’s massive $1.1 billion purchase of Bridge earlier this year, demonstrates the company’s commitment to building a comprehensive cryptocurrency infrastructure that could fundamentally reshape how businesses and consumers interact with digital assets.
Privy’s impressive scale provides immediate validation of the crypto wallet market’s maturity. With over 75 million accounts across more than 1,000 developer teams facilitating billions in transactions, the New York-based startup has proven that cryptocurrency wallets can achieve mainstream adoption when properly executed. Founded in 2021 by Henri Stern and Asta Li, Privy solved a critical problem in the crypto ecosystem by creating developer-friendly APIs that eliminate the technical barriers traditionally associated with wallet creation and blockchain integration.
The timing of this acquisition is particularly significant given the broader cryptocurrency market’s evolution toward practical utility rather than speculative trading. Privy’s technology spans multiple high-growth sectors including decentralized finance, gaming, artificial intelligence agents, and consumer applications, indicating that crypto infrastructure is becoming integral to diverse business models rather than remaining confined to niche financial applications.
Stripe’s strategic vision becomes clearer when considering how Privy’s capabilities complement the company’s existing strengths. The payments processor has built its reputation on simplifying complex financial operations for merchants, and cryptocurrency transactions represent the next logical frontier. By integrating Privy’s wallet technology with Bridge’s stablecoin infrastructure and Stripe’s global payment network, the company is creating a unified platform that could make cryptocurrency transactions as seamless as traditional card payments.
The acquisition’s structure reveals Stripe’s confidence in Privy’s independent value proposition. By allowing Privy to continue operating as an independent product, Stripe acknowledges that the crypto wallet market requires specialized expertise and dedicated focus. This approach mirrors successful technology acquisitions where the parent company provides resources and distribution while preserving the acquired company’s innovative culture and technical capabilities.
Patrick Collison’s statement about enabling “Internet-native financial services” hints at Stripe’s larger ambition to challenge traditional banking infrastructure. The combination of wallet technology, stablecoin capabilities, and global payment processing creates a powerful alternative to conventional financial systems, particularly for international transactions where traditional banking remains slow and expensive.
The undisclosed acquisition price, while notable, is less important than the strategic implications. Privy’s $40 million in raised capital from prominent investors including Ribbit Capital and Coinbase Ventures suggests a valuation multiple that reflects both current performance and future potential. For Stripe, which processes hundreds of billions in annual payment volume, the cost of this acquisition is minimal compared to the potential revenue from expanding into cryptocurrency infrastructure.
This acquisition positions Stripe to capture value from the inevitable growth in cryptocurrency adoption while maintaining its core business focus. As regulatory clarity improves and institutional adoption accelerates, companies with comprehensive crypto infrastructure will possess significant competitive advantages in the evolving digital economy.
LVAD patients face a high risk of bleeding events associated with oral anticoagulation alongside increased risk of cardiovascular (CV) events such as stroke
Hospitalization costs for patients following a major bleeding event associated with oral anticoagulation use averages $39,000 per event
Tecarfarin, with its novel metabolic pathway, potentially may offer an alternative to warfarin in this vulnerable population
PONTE VEDRA, Fla. – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing novel therapeutics for patients with cardiovascular disease, today announced new findings from third-party research on the economic and medical burdens faced by advanced heart failure patients with left ventricular assist devices (LVAD) requiring chronic anticoagulation.
The research recently conducted by Guidehouse, an AI-led professional services firm delivering advisory, technology, and managed services to the commercial and government sectors, underscores the significant clinical and economic burden for LVAD patients who require chronic oral anticoagulation. Key findings include:
Major bleeds remain a primary cost driver, with average hospitalization costs (per event) of $54,100 for intracranial hemorrhage, $26,900 for gastrointestinal bleeds, and $36,600 for other major bleeds.
Guidehouse’s analysis also identified tecarfarin – a novel, Phase 3-ready oral anticoagulant being developed by Cadrenal – as a potential alternative to warfarin to address the current unmet need in this patient population. Tecarfarin is designed to provide more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin. Its unique metabolism via a single enzyme (CES2) may reduce the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events.
“Despite decades of use, warfarin has significant limitations – especially in complex patients with LVADs,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “This research reinforces our conviction that tecarfarin has the potential to transform anticoagulation management for this high-risk population who currently has no alternative options.”
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease. Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used off-label for a number of indications, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal is advancing an innovative solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin and capture value in a market with high demand for safer, more manageable treatment options.
Cadrenal is pursuing a pipeline-in-a-product approach with tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including Left Ventricular Assisted Devices (LVADs). The Company also received ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib).
Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus on creating a pipeline of cardiovascular therapeutics. For more information, visit https://www.cadrenal.com/and connect with us on LinkedIn.
Safe Harbor
Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding Tecarfarin offering an alternative to warfarin for LVAD patients requiring chronic anticoagulation; providing more consistent anticoagulation control by avoiding the multiple metabolic pathways associated with warfarin; Tecarfarin’s metabolism via a single enzyme (CES2) reducing the risk of drug interactions, dietary complications, and adverse bleeding or thrombotic events; transforming anticoagulation management for LVAD patients who currently have no alternative options; preventing heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation; addressing the unmet needs in anticoagulation therapy; reducing the clinical complexities of warfarin; and capturing value in a market with high demand for safer, more manageable treatment options. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability of tecarfarin to provide clinical benefits for LVAD patients who require anticoagulation; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and other assets and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets, today announced its participation in NATO’s At-Sea Demonstration (ASD)/Formidable Shield (FS) 25. This extensive live-fire exercise, the largest of its kind in the European theater, is hosted biennially by the U.S. 6th Fleet and executed by Naval Striking and Support Forces NATO.
This year’s exercise comprised a series of live-fire events against unmanned air and surface systems, subsonic, supersonic, and ballistic targets. It incorporated multiple Allied ships, multi-national/multi-service ground-based air defenses, and aviation forces, working cohesively across battlespaces to deliver lethal effects, accomplish exercise objectives, and hone warfighting skills.
Kratos’ Aegis Readiness Assessment Vehicle Type B (ARAV-B) medium range ballistic missile target participated during the exercise. Kratos launched the ARAV-B target on May 20, 2025, which flew a nominal trajectory and performed all planned events before being successfully engaged and intercepted by U.S. guided missile destroyers USS Bulkeley (DDG-84) and USS Thomas Hudner (DDG-116) using a Standard Missile 3 (SM-3).
Dave Carter, President of the Kratos Defense & Rocket Support Services Division, said, “Kratos is immensely proud of our dedicated team of professionals who consistently contribute to the success of events like Formidable Shield for users worldwide. Our team continues to deliver affordable, responsive, and reliable threat representative targets to our government customers and their allies.”
Eric DeMarco, President and CEO of Kratos, said, “At Kratos, we deliver real, mission relevant products and systems to our customers, not powerpoints, renditions or imagination. We believe that affordability is a technology, and rather than pay dividends or buy back KTOS stock, we invest Kratos funds to rapidly develop and field National Security relevant hardware, innovating, and also saving our government customer and the U.S. taxpayer time and money compared to traditional approaches. Kratos’ participation in Formidable Shield 25 is a recent example of the success and value creation of Kratos’ strategy for our entire incredibly important stakeholder community.”
The exercise, which commenced on May 3, 2025, involved approximately 6,900 personnel from across NATO member states. Kratos has been supporting the biennial Formidable Shield Exercise with aerial drone and ballistic missile targets since its inception in 2017, continually offering NATO forces opportunities to test and improve interoperability in the integrated air and missile defense (IAMD) environment.
About Kratos Defense & Security Solutions Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, systems, and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital, and other investments to rapidly develop, produce, and field solutions that address our customers’ mission-critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven, bleeding-edge approaches, with Kratos’ approach designed to reduce cost, schedule, and risk, enabling us to be first to market with cost-effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems upfront for successful rapid, large-quantity, low-cost future manufacturing, which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles; jet-powered unmanned aerial drone systems; advanced vehicles and rocket systems; propulsion systems for drones, missiles, loitering munitions, supersonic systems, spacecraft, and launch systems; C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter-UAS, directed energy, communication, and other systems; and virtual and augmented reality training systems for the warfighter. For more information, visit http://www.kratosdefense.com.
Notice Regarding Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.
Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.
Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Solid Q1 Results. The company reported Q1 revenue of $97.0 million and adj. EBITDA of $15.6 million, both of which easily surpassed our estimates of $87.0 million and a loss of $0.6 million, respectively. Notably, while revenue decreased 9% from last year, adj. EBITDA was up substantially from a loss of roughly $1.0 million. The improvement in adj. EBITDA was largely driven by the company’s efficient use of marketing spend and focus on profitability.
Key operating metrics. Bookings and monthly paying users decreased by 25% and 26%, respectively, compared to the prior year period, but the decrease was expected as the company is focused on improving the quality of gameplay and not over-monetizing its user base. For example, average bookings per paying user (ABPPU) increased from $88 in Q1’24 to $90 in Q1’25, despite a decrease in monthly paying users.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Acquisition. CoreCivic is expanding its Safety Segment with the proposed acquisition of The Farmville Detention Center in Farmville, Virginia, about 60 miles west of Richmond. Constructed in 2010, Farmville is a 736-bed facility that provides transportation, care, and civil detention services to adult male noncitizens through an Intergovernmental Service Agreement between Prince Edward County, Virginia, and U.S. Immigration & Customs Enforcement (“ICE”), which expires in March 2029.
Details. CoreCivic is paying $67 million for Farmville, or about $91,000 per bed. The transaction is expected to be funded with cash on hand and borrowings under the Company’s revolving credit facility. The acquisition is expected to close effective July 1st and will add approximately $40 million of incremental revenue on an annual basis. Using the Safety segment’s average 2024 operating margin, Farmville could add nearly $10 million of segment operating income on an annual basis.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the bottom of the report for important disclosures
Demand for rare earth elements expected to grow. Demand for rare earth elements is expected to grow meaningfully through 2030 and beyond, driven by electric vehicles, wind turbines, grid upgrades, and advanced defense technologies. According to the IEA, global rare earth demand could double by 2050 under a net-zero scenario, underscoring the growing strategic relevance in the global energy transition.
China dominates the REE market. According to the 2024 edition of the Energy Institute Statistical Review of World Energy, China accounted for 67.9% of rare earth mineral production in 2023 and 38.1% of rare earth mineral reserves, while accounting for most of the midstream and downstream capacity. While mining activity is gradually diversifying, the refining stage remains concentrated. This level of concentration poses a risk to both the U.S. supply chain and national security.
U.S. policymakers seek to reduce dependence on China. U.S. policymakers are increasingly focused on reducing dependence on China for rare earth elements, viewing it as a national security and industrial resilience issue. Recent actions include invoking the Defense Production Act, funding domestic processing projects, and expanding international partnerships through initiatives like the Minerals Security Partnership. Legislative efforts and strategic investments are aimed at reshoring supply chains and building alternative capacity in allied countries such as Canada and Australia.
Necessity is the mother of invention. While the Trump Administration is taking appropriate action and policy momentum is growing, the path to increasing rare earth supply chain independence is complex and will take time. Policymakers may need to work with allies, such as Canada, to promote a North American supply chain that encompasses all aspects of the REE value chain, including upstream, midstream, and downstream. In addition to supportive public policy, private industry will likely need financial support from governments to kick start the effort.
Metals and Mining Spotlight: Rare Earth Elements
Rare earth elements (REEs) are comprised of 15 elements in the lanthanum series, along with scandium and yttrium. While not lanthanides, scandium and yttrium are classified as rare earth elements because they occur within the same ore deposits and share similar chemical properties. While the actual elements may not be rare, it is often difficult to find them in sufficient concentrations for economic extraction, and they require extensive processing. Cerium, lanthanum, neodymium, praseodymium, and promethium are considered light rare earth elements. Europium, gadolinium, and samarium are often referred to as medium rare earth elements, while dysprosium, erbium, holmium, lutetium, terbium, thulium, and ytterbium are considered heavy rare earth elements. We do not classify scandium (Sc) or yttrium (Y) as light, medium, or heavy. Below is a table summarizing the elements and their symbols.
Figure 1: Rare Earth Elements and Atomic Number and Symbol
Source: Noble Capital Markets, Inc.
One of the many uses of rare earth elements is in the production of permanent magnets which are critical components in electric vehicles, wind turbines, and other communication and defense technologies. Neodymium and praseodymium are critical materials in the manufacturing of neodymium-iron-boron (NdFeB) magnets, which have among the highest magnetic strength among commercially available magnets and promote high energy density and efficiency in energy technologies. They are often referred to as NdPr magnets because they generally contain about one-third neodymium, of which some of that can be replaced by praseodymium. While REEs are used for a variety of applications, the highest value REEs are neodymium and praseodymium, which currently drive the value of mixed rare earth concentrates and precipitates. By economic value, neodymium-praseodymium (NdPr) is the largest segment of the REE market. NdPr is primarily used in neodymium-iron-boron (NdFeB) permanent magnets for electric machines, such as electric vehicle (EV) traction motors, wind power generators, drones, robotics, electronics, and other applications. Given the wide-ranging uses of these component materials in critical infrastructure essential for national security and economic growth, the U.S. government has taken an interest in industry concentration.
Figure 2: Rare Earth Applications
Source: National Energy Technology Laboratory
According to the 2024 edition of the Energy Institute Statistical Review of World Energy, China accounted for 67.9% of rare earth mineral production in 2023 and 38.1% of rare earth mineral reserves. Conversely, the United States accounted for 12.2% of rare earth mineral production in 2023 and 1.6% of rare earth mineral reserves.
Figure 3: Rare Earth Metals Production and Reserves
Source: Energy Institute Statistical Review of World Energy 2024
Supply Chain and Pricing Overview
The supply chain for rare earths includes upstream, midstream, and downstream components.
Figure 4: Rare Earth Element Supply Chain
Source: Critical Materials Rare Earths Supply Chain: A Situational White Paper, U.S. Department of Energy, Office of Energy Efficiency & Renewable Energy, April 2020
As illustrated in Figure 4, concentration or beneficiation is an extractive metallurgy process that upgrades the value of mineral ores that contain raw REEs by removing low value minerals and resulting in a higher-grade product such as rare-earth concentrate.
Separation is the process of separating individual REEs from one another in the rare earth oxide (REO) concentrates. Separation of REEs is chemically intensive because the REEs are chemically similar. Processing refers to the conversion of REOs to rare earth metals, such as neodymium metal which can then be used to form alloys. China controls most of the midstream separating and processing capacity.
There is no single price for REEs collectively, but numerous prices for REE oxides and compounds individually. Pricing information for rare earths is opaque and generally available by paid subscription. Public information is generally not comprehensive and generally does not provide detailed information as to quality and origin, which makes comparisons difficult. Below we have provided a pricing sample of the most valuable elements as of June 11, 2025.
Figure 5: Pricing Data for Select Rare Earth Elements (REE)
Source: Strategic Metals Invest
U.S. Rare Earth Element Market
According to the U.S. Department of the Interior, the estimated value of rare-earth compounds and metals imported by the United States in 2023 was $190 million, down 7% from $208 million in 2022. Catalysts represented the leading domestic end use for rare earths, followed by applications in ceramics and glass, metallurgical alloys, polishing, and embedded permanent magnets in finished goods. While rare earth recycling is expected to grow in the coming years, current recovery rates from sources such as batteries and permanent magnets remain limited. The table below provides some statistics associated with the rare earths market in the United States.
Figure 6: United States REE Market Statistics
Source: Mineral Commodity Summaries 2024, U.S. Department of the Interior, U.S. Geological Survey
Given the United States’ reliance on imports, we think Canadian producers stand to benefit from a shift away from sources in China. As processing capabilities are developed, the U.S. could be an important destination for Canada sourced materials.
Key REE Market Participants
The global rare earth industry remains defined by a limited number of dominant players, most of which are concentrated in China. China Northern Rare Earth Group (SHH: 600111), and China Minmetals are the largest vertically integrated producers, with strong government alignment and control over both upstream mining and midstream separation capacity. These firms benefit from large-scale infrastructure, domestic demand, and preferential access to processing technology that remains restricted from foreign use.
Outside China, Lynas Rare Earths (ASX: LYC, OTC: LYSDY), in Australia is the largest fully integrated producer, with upstream operations at Mount Weld and a separation plant in Malaysia. Lynas is expanding into heavy rare earth processing in Texas through a strategic partnership with the U.S. Department of Defense.
MP Materials, the most significant rare earth materials producer in the United States, completed a business combination with Fortress Value Acquisition Corp., a special purpose acquisition company and began trading on the New York Stock Exchange on November 18, 2020, under the ticker MP. MP Materials owns and operates the Mountain Pass rare earth mine and processing facility in California which opened in 1952 as a uranium producer, pivoted to one of the largest suppliers of rare earth minerals, but closed in 2002 as environmental restrictions and imports made it difficult to compete. The facility underwent various ownership changes and reopened in 2017 under MP Materials’ ownership. It is North America’s only active and scaled rare earth production site and now has a market capitalization of $4.1 billion as of June 11, 2025.
The Mountain Pass mine in California and is the only active rare-earth mine in the United States. The company has restarted oxide production and is building refining and alloying capacity in Texas. MP has signed multi-year offtake agreements with original equipment manufacturers (OEMs), including General Motors, aimed at creating a vertically integrated domestic supply chain. However, the company still relies on China to assist in the separation process for some of its output, underscoring the current U.S. capabilities gap.
Additional participants working to expand non-Chinese supply chains include Iluka Resources (ASX: ILU, OTC: ILKAF) and Arafura Rare Earths (ASX: ARU, OTC: ARAFF), both based in Australia. Iluka is building a new facility with support from the Australian government, aimed at handling all stages of rare earth production. Arafura is also developing a new project with backing from international lenders, focused on supplying materials used in magnets for electric motors and other technologies. On the downstream side, magnet production is dominated by firms such as Shin-Etsu (TSE: 4063, OTC: SHECY), Hitachi Metals, and JL MAG (SZSC: 300748, OTC: JMREY), with capacity heavily skewed toward Asia. Efforts among U.S. and allied countries to establish domestic magnet manufacturing are progressing but remain in the early stages.
China dominates the production of many critical minerals, including rare earth elements. There appears to be an awakening among U.S. policy makers of the dangers of dependence on foreign sources for critical minerals, especially those that are adversarial to the United States. We believe a shift is underway to source REEs from countries that are friendly to the United States, including Canada. As part of its strategy to ensure secure and reliable supplies of critical minerals, the U.S. Department of the Interior identified 35 critical minerals, including the rare earth elements group. The U.S. Government is planning to fund rare earths projects to reduce reliance on China. In January 2022, bipartisan legislation was introduced, the Restoring Essential Energy and Security Holdings Onshore for Rare Earths Act, to protect the U.S. from the threat of rare-earth element supply disruptions, encourage domestic production, and reduce reliance on China. REEs are found in mineral deposits such as bastnaesite and monazite, the two largest sources of REEs. Bastnaesite, a carbonate-fluoride mineral, typically contains cerium, lanthanum, neodymium, and praseodymium. Monazite, a phosphate mineral, typically contains cerium, lanthanum, neodymium, and samarium. Rare earths are mined domestically in the United States. Bastnaesite is extracted at the mine in Mountain Pass, California.
Since January 2025, the Trump administration has significantly expanded its strategic focus on rare earth supply chain security. In April, an executive order initiated an investigation into whether U.S. dependence on foreign sources of rare earths constitutes a national security threat. An additional order opened up new offshore exploration zones for critical minerals, including seabed areas believed to contain rare earth and battery metals.
Furthermore, the administration has invoked the Defense Production Act to allocate capital and permit support to midstream and downstream segments of the rare earth supply chain. MP Materials began producing rare earth metals at its Texas facility, while Lynas advanced its U.S. processing plant with support from the Department of Defense. These efforts are part of a broader strategy to rebuild U.S. capabilities across the rare earth value chain.
International partnerships have also gained momentum. The U.S. is advancing cooperation with Australia, Canada, and Ukraine to secure alternative sources of supply and coordinate project financing through the Minerals Security Partnership. A bilateral agreement with Ukraine is expected to facilitate exploration and development of new deposits, while Australia remains a primary ally for both upstream mining and technical collaboration.
Outlook
The rare earth industry is entering a period of strong growth and growing strategic relevance. According to the International Energy Agency (IEA), magnet-grade rare earth demand could double by 2050, and mining projects could rise by 52% by 2040, under current policy (IEA, Critical Minerals Report, 2024). These forecasts are driven by growth in electric vehicle drivetrains, offshore wind development, and precision defense systems, all of which rely heavily on rare earth magnets for performance, efficiency, and miniaturization. As a result, rare earths have transitioned from niche industrial inputs to core strategic resources.
Figure 7: REE Demand Outlook and Mining Requirements (kt REE)
Source: Global Critical Minerals Outlook 2024, International Energy Agency (IEA)
We note that the IEA’s forecasts are based on three scenarios. These include: 1) the Stated Policies Scenario (STEPS), 2) the Announced Pledges Scenario (APS), and 3) the Net Zero Emissions by 2050 Scenario (NZE). The Stated Policies Scenario is based on current policy settings. The Announced Pledges Scenario assumes that governments will meet all climate-related commitments they have announced, including net zero emissions targets. The Net Zero Emissions by 2050 Scenario represents a pathway for the global energy sector to achieve net zero carbon dioxide emissions by 2050. These are summarized, of course, and readers may consult the IEA’s report for a more detailed description.
In the short term, challenges will continue to shape how supply chains evolve outside of China. Most new projects in Western countries face long approval timelines due to environmental reviews, local opposition, and infrastructure gaps. While government funding and procurement support are improving, the limited availability of midstream processing remains a key constraint.
In our view, rare earths are evolving from niche industrial inputs to foundational resources for advanced economies. Although the industry currently operates at a scale that lags its growing strategic importance, recent policy momentum and expanded investment across allied nations are setting the stage for meaningful transformation. Looking ahead, we expect a more balanced and resilient global supply chain to emerge—anchored by deepening cooperation between the United States, Canada, Australia, and European partners. While China will remain a major player in the near term, the diversification of supply chains is gaining traction, signaling a shift toward greater self-sufficiency and long-term security among like-minded nations.
GENERAL DISCLAIMERS
All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.
This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results. Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.
IMPORTANT DISCLOSURES
This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report. The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.
Company Specific Disclosures
The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report. Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months
ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE
Senior Equity Analyst focusing on Basic Materials & Mining. 20 years of experience in equity research. BA in Business Administration from Westminster College. MBA with a Finance concentration from the University of Missouri. MA in International Affairs from Washington University in St. Louis. Named WSJ ‘Best on the Street’ Analyst and Forbes/StarMine’s “Best Brokerage Analyst.” FINRA licenses 7, 24, 63, 87
WARNING
This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc..
RESEARCH ANALYST CERTIFICATION
Independence Of View All views expressed in this report accurately reflect my personal views about the subject securities or issuers.
Receipt of Compensation No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public appearance and/or research report.
Ownership and Material Conflicts of Interest Neither I nor anybody in my household has a financial interest
